Dollars for Profs
Dig Into University Researchers' Outside Income and Conflicts of Interest
Published Dec. 6, 2019
This database was last updated in December 2019 and should only be used as a historical snapshot. There may be new or amended records not reflected here.
Conflict of Interest
Institutions must file significant disclosures to the National Institutes of Health if they determine financial relationships could affect the design, conduct or reporting of the NIH-funded research. The NIH provided us with their entire financial conflict of interest database, with filings from 2012 through 2019.
Should you be removed from our database? Contact us at [email protected]. Read more below.
Scott Armstrong
Dana Farber Cancer Inst, Department: Na
Should you be removed from our database? Contact us at [email protected]. Read more below.
C4 Therapeutics
Equity Interest - Non-publicly traded entity ( e.g., stock, stock option, or other ownership interest)
NA
Targeting DOT1L for Degradation in MLL-rearranged Leukemia
Project Narrative Despite recent progress in our understanding of MLL-rearranged (MLL-r) leukemias, the disease remains difficult to cure, establishing an area of significant unmet medical need. While the first targeted therapies against DOT1L, an enzyme important for survival of MLL-r leukemia, have been realized in human clinical trials, early evidence suggests that resistance to these inhibitors has emerged. In this study, we will seek to define the biological foundation for acquired resistance to DOT1L therapy and overcome resistance through the development and optimization of a new class of small molecules that can degrade DOT1L protein, thus developing the tools and fundamental preclinical knowledge to help overcome this devastating disease.
Filed on September 12, 2018.
Tell us what you know about Scott Armstrong's disclosure
We're still reporting about conflicts of interest. Is there something you'd like to tell us about this disclosure?
Scott Armstrong filed other conflict of interest disclosures with the NIH:
| Name | Institution | Type | Company | Disclosed Value |
|---|---|---|---|---|
| Scott Armstrong | Dana Farber Cancer Inst | Conflict of Interest | C4 Therapeutics | $20,000 - $39,999 |
| Scott Armstrong | Dana Farber Cancer Inst | Conflict of Interest | Epizyme, Inc. | $5,000 - $9,999 |
| Scott Armstrong | Dana Farber Cancer Inst | Conflict of Interest | Epizyme, Inc. | $0 - $4,999 |
Notes: When a more specific filing date is not available for an individual financial disclosure or conflict of interest form, we use the year the form was filed. If the year was not disclosed, we report the range of years covered by our public records requests. In a few cases, a start date was provided instead of a filing date. In those cases, we use the start date instead.
Fewer than 10% of records from the University of Florida and fewer than 1% of records from the University of Texas system were removed because they did not contain enough information.
ProPublica obtained additional financial disclosures and conflict of interest forms that we have not yet digitized and added to the database. You can download those disclosures in the ProPublica Data Store.